KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other financing activities: 2017-2025

  • Amneal Pharmaceuticals' Other financing activities was N/A to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.7 million, marking a year-over-year change of. This contributed to the annual value of $162.4 million for FY2023, which is 9666.39% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Other financing activities of $73.2 million as of Q3 2025, which was down 54.76% from $161.9 million recorded in Q4 2023.
  • Amneal Pharmaceuticals' 5-year Other financing activities high stood at $161.9 million for Q4 2023, and its period low was $41,000 during Q3 2022.
  • Over the past 2 years, Amneal Pharmaceuticals' median Other financing activities value was $73.2 million (recorded in 2025), while the average stood at $78.5 million.
  • Data for Amneal Pharmaceuticals' Other financing activities shows a peak YoY skyrocketed of 1,221.95% (in 2023) over the last 5 years.
  • Amneal Pharmaceuticals' Other financing activities (Quarterly) stood at $41,000 in 2022, then soared by 1,221.95% to $161.9 million in 2023, then reached $73.2 million in 2025.
  • Its Other financing activities stands at $73.2 million for Q3 2025, versus $161.9 million for Q4 2023 and $542,000 for Q3 2023.